Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-HNSCC: Volrustomig vs Observation After Definitive cCRT in Unresected LA-HNSCC
jRCT2041230127Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Volrustomig maintenance with Observation (2 arms). Primary endpoint: Progression-Free Survival (PFS) in PD-L1 expressing tumors. Started Feb 2024; status: recruiting.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2041230127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230127.